我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

PCI术后双联抗血小板药物治疗的最佳维持剂量

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2014年第5期
页码:
614-617
栏目:
综述
出版日期:
2014-05-25

文章信息/Info

Title:
Optimal maintenance dose of dual antiplatelet therapy after percutaneous coronary intervention
作者:
郭艳杰; 陈 迈; 李伟杰
(第四军医大学西京医院心血管内科，陕西 西安 710032)
Author(s):
GUO Yan-jie;  CHEN Mai;  LI Wei-jie
(Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China)
关键词:
经皮冠脉介入治疗; 阿司匹林; 氯吡格雷
Keywords:
percutaneous coronary intervention;  aspirin;  clopidogrel
分类号:
R973
DOI:
-
文献标识码:
A
摘要:
经皮冠脉介入手术（PCI）已成为解除冠脉血管严重狭窄的主要非外科治疗方法，术后双联抗血小板药物的治疗可有效地预防各种血栓性并发症，减低心血管事件的发生及死亡率。近年来，在PCI后，阿司匹林及氯吡格雷的最佳维持剂量方面存在很多争议，本文就此问题结合大量国内外的研究及指南推荐进行综述，并对新型抗血小板药物的应用前景进行展望。
Abstract:
Percutaneous coronary intervention (PCI) is the main non-surgical method for releasing severe coronary stenosis. Postoperative dual antiplatelet drug therapy can effectively prevent the emergence of various thrombotic complications and reduce the occurrence of cardiovascular events and mortality. However, in recent years, there has been much controversy over the best maintenance dose of aspirin and clopidogrel after PCI. The article reviews large numbers of studies and guidelines both at home and abroad and discusses the application prospect of new antiplatelet agents.

参考文献/References

[1]Bowry AD,Brookhart MA,Choudhry NK.Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events[J].Am J Cardiol,2008,101(7):960-966.
[2]Lee CW,Ahn JM,Park DW,et al.Optimal duration of dual antiplatelet therapy after drug-eluting stent Implantation:a randomized controlled trial[J].Circulation,2014,129(3):304-312.
[3]Jolly SS,Pogue J,Haladyn K,et al.Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention:insights from the PCI-CURE study[J].Eur Heart J,2009,30(8):900-907.
[4]Mehta SR,Tanguay JF,Eikelboom JW,et al.Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial[J]. Lancet,2010,376(9748):1233-1243.
[5]Lotfi A,Cui J,Wartak S,et al.Influence of low-dose aspirin(81 mg)on the incidence of definite stent thrombosis in patients receiving bare-metal and drug-eluting stents[J].Clin Cardiol, 2011,34(9):567-571.
[6]Yu J,Mehran R,Dangas GD,et al.Safety and efficacy of high- versus low-dose aspirin after primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial［J］. JACC Cardiovasc Interv,2012,5(12):1231-1238.
[7]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.经皮冠状动脉介入治疗指南(2009)[J].中华心血管病杂志,2009,37(1):4-25.
[8]中华医学会心血管病学分会介入心脏病学组,中华心血管病杂志编辑委员会.2012年中国经皮冠状动脉介入治疗指南(简本)[J].中华心血管病杂志,2012,40(4):271-277.
[9]Levine GN, Bates ER,Blankenship JC,et al.2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J].Circulation,2011,124(23):574-651.
[10]Taylor J.2012 ESC Guidelines on acute myocardial infarction (STEMI)[J].Eur Heart J,2012,33(20):2501-2502.
[11]Harold JG,Bass TA,Bashore TM,et al.ACCF/AHA/SCAI 2013 update of the clinical competence statement on coronary artery interventional procedures:a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training(Writing Committee to Revise the 2007 Clinical Competence Statement on Cardiac Interventional Procedures)[J].J Am Coll Cardiol 2013,62(4):357-396.
[12]Mehta SR,Tanguay JF,Eikelboom JW,et al.Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7):a randomised factorial trial[J].Lancet,2010,376(9748):1233-1243.
[13]Price MJ,Berger PB, Teirstein PS,et al.Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial[J].JAMA,2011,305(11):1097-1105.
[14]Mega JL,Close SL,Wiviott SD,et al.Cytochrome p-450 polymorphisms and response to clopidogrel[J].N Engl J Med,2009,360(4):354-362.
[15]Sibbing D,Koch W,Gebhard D,et al.Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J].Circulation,2010,121(4):512-518.
[16]Mega JL,Hochholzer W,Frelinger AL,et al.Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease[J].JAMA,2011,306(20):2221-2228.

备注/Memo

备注/Memo:
收稿日期：2014-01-16.
通讯作者：陈迈，主治医师，主要从事冠心病研究 Email：chenmai77@hotmail.com
作者简介：郭艳杰，住院医师，硕士 Email：qing090909@sina.com
更新日期/Last Update: 2014-06-05